-
Terrific Care, LLC. / Medex Supply Dist, Inc. issues Nationwide Recall of CoaguChek Test Strips
Thursday, December 27, 2018This announcement clarifies information included in Terrific Care, LLC's press release issued on 12/19/2018 On 12/19/2018, Terrific Care, LLC. / Medex Supply Dist, Inc. initiated a nationwide recall of Roche CoaguChek test strips distributed directly to U.S. consumers by Terrific Care, LLC. / Medex... Read More -
Fluoroquinolone Antibiotics: Safety Communication - Increased Risk of Ruptures or Tears in the Aorta Blood Vessel in Certain Patients
Thursday, December 27, 2018FDA review found that fluoroquinolone antibiotics can increase the occurrence of rare but serious events of ruptures or tears in the main artery of the body, called the aorta. These tears, called aortic dissections, or ruptures of an aortic aneurysm can lead to dangerous bleeding or even death. ... Read More -
Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP
Thursday, December 27, 2018Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.
Read More -
Mylan Expands Its Voluntary Nationwide Recall
Monday, December 10, 2018Mylan N.V. (NASDAQ: MYL) today (12/4/2018) announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths).
Out of an abundance of caution, these products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Valsartan, USP, manufactured by Mylan Laboratories Limited. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).
Read More
Home
- About
- Careers
- Contact Us
- Medicare Quality Improvement (QIO)
- HSAG HQIC Partnership
-
ESRD Networks Home
- About Us
- Contact Us
- For Patients and Families
- For Providers
- ESRD Network 7
- ESRD Network 13
- ESRD Network 15
- ESRD Network 17
- ESRD Network 18
- HSAG ESRD Alerts, Recalls, and Notices
- Behavioral Health
- Continuing Education
- Data Management
- Emergency Preparedness
- Health Equity and CLAS
- Home Dialysis
- Infection Prevention
- Patient and Family Engagement (PFE)
- Readmissions and Hospitalizations
- Telemedicine
- Transplant
- Vaccinations
- Healthcare Policy and Quality Measurement
- Medicaid External Quality Review
- QPP Service Center
- Surveys
- Audit and Validation Services (HEDIS®/AMP)
- News